An Open-label, Randomized, Phase 3 Clinical Trial of ABX-EGF Plus Best Supportive Care Versus Best Supportive Care in Subjects With Metastatic Colorectal Cancer.
Latest Information Update: 20 Jul 2022
At a glance
- Drugs Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
- Sponsors Amgen
- 07 Jun 2022 Results (n=461) of an analysis assessing predictive score to identify patients who are likely to benefit from Panitumumab treatment between differential variables subgroups using data from three clinical studies: NCT00364013, NCT00339183 and NCT00113763 presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2021 Results assessing disease progression and mortality based on clinical parameters in chemo naive and chemo-refractory patients from two clinical studies: NCT00364013 and NCT00113763 presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.